Stryker Corporation’s Orthopaedics division and OrthoSensor™, Inc., the self-styled leader in intelligent orthopedics, have announced an extension of their co-marketing agreement for Stryker’s Triathlon Knee System and OrthoSensor’s VERASENSE. VERASENSE is an intelligent instrument system that provides quantitative, intra-operative feedback to surgeons to optimize joint balance during total knee arthroplasty.
Another orthopaedic giant, Biomet signed a similar deal with OrthoSensor last April as we reported here.
OrthoSensor’s VERASENSE is an intelligent, low-cost, single-use instrument system that replaces the standard plastic tibial trial spacer used during knee replacement surgery. The system uses advanced proprietary sensor and communications technologies to give surgeons real-time feedback on soft tissue balance during knee-replacement surgery. This quantitative data enables surgeons to make informed, evidence-based adjustments to the soft tissues and implant placement.
The Triathlon Knee System is designed to promote ligament balance through the active range of motion to enhance stability and mobility, even during mid-flexion. A study showed that select patients without post-op complications who received Stryker’s single radius knee replacement abandoned crutches sooner and required fewer physiotherapy sessions than patients with traditional knee replacements.
“The single radius design philosophy of Stryker knees is a perfect complement to OrthoSensor’s innovative technology,” said Patrick Treacy, Vice President and General Manager of knee reconstruction at Stryker Orthopaedics. “The Triathlon Knee System is suited to the finer elements of ligament balancing and being able to take advantage of this new offering provides us with the opportunity to combine our advanced orthopaedic implant technology with innovative sensor technology.”
“Since launching OrthoSensor’s first intraoperative surgical system last year, over 35 orthopedic centers of excellence have adopted our technology and as demand continues to accelerate, we are delighted to extend our agreement with Stryker,” said Jay Pierce, CEO of OrthoSensor. “VERASENSE provides surgeons with intraoperative data to quantify and verify that they balance a knee implant during total knee arthroplasty. By enabling surgeons to make evidence-based, intraoperative decisions, we can help improve patient care, measure clinical outcomes and help lower the cost of treating musculoskeletal disease.”
Source: Stryker Corporation